A review of three stand-alone topical thrombins for surgical hemostasis

Clinical Therapeutics

Volumn 31, Issue 1, 2009, Pages 32-41

  Cheng, Christine M ^a   Meyer Massetti, Carla ^a   Kayser, Steven R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

bovine thrombin; human thrombin; recombinant thrombin; topical thrombin

Indexed keywords

BLOOD CLOTTING FACTOR 5; BOVINE PLASMA DERIVED THROMBIN; CROSS REACTING ANTIBODY; EVITHROM; HUMAN PLASMA DERIVED THROMBIN; HUMAN RECOMBINANT THROMBIN; PLACEBO; RECOTHROM; THROMBIN DERIVATIVE; THROMBIN JMI; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; BLEEDING; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG USE; HEART DISEASE; HEMOSTASIS; HUMAN; IMMUNOGENICITY; INCIDENCE; INFECTION; INSOMNIA; MEDICAL LITERATURE; MEDLINE; NAUSEA; NAUSEA AND VOMITING; PAIN; PHARMACOECONOMICS; REVIEW; RISK; THAWING; THROMBOEMBOLISM; VOMITING;

ADMINISTRATION, TOPICAL; ANIMALS; CATTLE; DRUG COSTS; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS; THROMBIN; UNITED STATES;

EID: 60349108060     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.01.005     Document Type: Review

References (25)

1. Spotnitz W.D., and Burks S. Hemostats, sealants, and adhesives: Components of the surgical toolbox. Transfusion 48 (2008) 1502-1516
2. Lawson J.H. The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost 32 Suppl 1 (2006) 98-110
3. Heffernan J.K., Ponce R.A., Zuckerman L.A., et al. Preclinical safety of recombinant human thrombin. Regul Toxicol Pharmacol 47 (2007) 48-58
4. Terrab A., Pawlak D., Spaay P., et al. Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step. Clin Appl Thromb Hemost 14 (2008) 135-140
5. Sarfati M.R., Dilorenzo D.J., Kraiss L.W., and Galt S.W. Severe coagulopathy following intraoperative use of topical thrombin. Ann Vase Surg 18 (2004) 349-351
6. Thrombin-JMI [package insert] (November 2007), King Pharmaceuticals, Inc, Bristol, Tenn
7. Evithrom Formulary Kit (September 2007), Johnson & Johnson Wound Management, Somerville, NJ
8. Recothrom Formulary Kit (January 2008), ZymoGenetics Inc, Seattle, Wash
9. Christie R.J., Carrington L., and Alving B. Postoperative bleeding induced by topical bovine thrombin: Report of two cases. Surgery 121 (1997) 708-710
10. Coughhn S.R. Protease-activated receptors in hemostasis, thrombosis and vascular biology. J Thromb Haemost 3 (2005) 1800-1814
11. Streiff M.B., and Ness P.M. Acquired FV inhibitors: A needless iatrogenic complication of bovine thrombin exposure. Transfusion 42 (2002) 18-26
12. Ortel T.L., Mercer M.C., Thames E.H., et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg 233 (2001) 88-96
13. Shander A., and Javidroozi M. The unresolved safety concerns of bovine thrombin. Patient Saf Surg 2 (2008) 23
14. Pavlovich C.P., Battiwalla M., Rick M.E., and Walther M.M. Antibody induced coagulopathy from bovine thrombin use during partial nephrectomy. J Urol 165 (2001) 1617
15. La Spada A.R., Skålhegg B.S., Henderson R., et al. Brief report: Fatal hemorrhage in a patient with an acquired inhibitor of human thrombin. N Engl J Med 333 (1995) 494-497
16. Winterbottom N., Kuo J.M., Nguyen K., et al. Antigenic responses to bovine thrombin exposure during surgery: A prospective study of 309 patients. J Appl Res 2 (2002) 20-29
17. Zehnder J.L., and Leung L.L. Immunological consequences of topical bovine thrombin. Am J Pathol 159 (2001) 2371
18. Chapman W.C., Lockstadt H., Singla N., et al. Phase 2, randomized, double-blind, placebo-controlled, multicenter clinical evaluation of recombinant human thrombin in multiple surgical indications. J Thromb Haemost 4 (2006) 2083-2085
19. Chapman W.C., Singla N., Genyk Y., et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg 205 (2007) 256-265
20. Weaver F.A., Lew W., Granke K., et al. for the Study Investigators. A comparison of recombinant thrombin to bovine thrombin as a hemostatic ancillary in patients undergoing peripheral arterial bypass and arteriovenous graft procedures. J Vase Surg 47 (2008) 12661273
21. Dona C., Fischer C.P., Wood C.G., et al. Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine thrombin in achieving hemostasis in patients undergoing surgery. Curr Med Res Opin 24 (2008) 785-794
22. Aebersold P. Food and Drug Administration Center for Biologies Evaluation and Research: Product Approval Information for recombinant thrombin. http://www.fda.gov/cber/products/recothrom/recothrom111107mem.htm Accessed August 3, 2008
23. Drug Topics Red Book (Update) (December 2008), Thomson Reuters, Mont-vale, NJ
24. Drug Topics Red Book 698 (2008), Thomson Healthcare, Montvale, NJ 752
25. ReadyPrice Monthly (April 2008), Thomson Micromedex, Montvale, NJ